滚动资讯
FierceBiotechLilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience playFierceBiotechBMS links up with Faro to use AI to improve clinical trial protocolsFierceBiotechObesity biotech Ambrosia scores $100M series B to take next-gen oral GLP-1 into the clinicFierceBiotechStill reeling from FDA refusal, IO Biotech surrenders to bankruptcyEndpoints NewsColorado biotech Ambrosia lands $100M for oral GLP-1Endpoints NewsAstellas doesn’t pick up AviadoBio’s gene therapy, but nonprofit funding will move it forwardLonza NewsLonza links up with Torqur on bimiralisib manufacturing - The Pharma LetterBioPharma DiveViridian tumbles on positive data for key eye drug prospect10x Genomics Blog10x Genomics (NASDAQ:TXG) Shares Gap Up Following Analyst Upgrade - MarketBeatPromega BlogDown the Rabbit Hole: The Search for New England’s Disappearing CottontailAgilentIs New Esophageal Cancer Keytruda Test Approval Reshaping The Investment Case For Agilent Technologies (A)? - simplywall.stEndpoints NewsAvo raises $10M to help clinicians with workflow
FierceBiotech 2026年3月31日

Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play

Lilly pays $6.3B upfront for sleep disorder-focused Centessa in latest neuroscience play

原文
暂时没有全文，请查看原始来源。

目录

59 全部